Forte Biosciences (FBRX) awards 500,000 stock options to insider Wagner

Rhea-AI Filing Summary

Forte Biosciences director and officer Paul A. Wagner received a grant of stock options for 500,000 shares of Common Stock. The options have an exercise price of $17.15 per share and expire on June 16, 2036. This is a compensation-related award, not an open-market purchase.

According to the vesting terms, beginning on the Vesting Commencement Date of June 16, 2026, one forty-eighth of the options vest each month, so the award becomes fully vested over four years if he continues as a service provider.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wagner Paul A.

Role SEE REMARKS

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	500,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 500,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 500,000 options Exercise price: $17.15 per share Expiration date: June 16, 2036 +2 more

5 metrics

Stock options granted 500,000 options Grant of Stock Option (right to buy) on June 16, 2026

Exercise price $17.15 per share Exercise price for the 500,000 stock options

Expiration date June 16, 2036 Option expiration for Wagner’s grant

Underlying shares 500,000 shares Common Stock underlying the stock options

Vesting schedule 1/48 monthly over 4 years From Vesting Commencement Date June 16, 2026

Key Terms

Stock Option (right to buy), Vesting Commencement Date, 2021 Equity Incentive Plan, Service Provider

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Vesting Commencement Date financial

"“Vesting Commencement Date” shall mean June 16, 2026."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

2021 Equity Incentive Plan financial

"as defined in the 2021 Equity Incentive Plan"

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wagner Paul A.

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BLDG 6

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$17.15	06/16/2026		A		500,000		(1)	06/16/2036	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 16, 2026.

Remarks:

CEO, Secretary and Chair of the Board

	/s/ Paul A. Wagner, Ph.D.	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Forte Biosciences (FBRX) report in this Form 4 for Paul A. Wagner?

Forte Biosciences reported that Paul A. Wagner received a grant of stock options for 500,000 shares of Common Stock. These options are a compensation-related award and not an open-market purchase of existing shares by the insider.

What is the exercise price and expiration date of Paul A. Wagner’s new FBRX stock options?

The granted stock options have an exercise price of $17.15 per share and expire on June 16, 2036. This means Wagner can buy shares at $17.15 any time before the expiration date, once the options have vested under the plan’s terms.

How do the newly granted Forte Biosciences (FBRX) options vest for Paul A. Wagner?

The options vest monthly over four years, starting from the Vesting Commencement Date of June 16, 2026. One forty-eighth of the 500,000 options vests each month, so the full award vests if Wagner continues as a service provider throughout this period.

How many Forte Biosciences (FBRX) derivative securities does Paul A. Wagner hold after this grant?

After this transaction, Wagner holds 500,000 stock options according to the filing. These options each relate to one share of Common Stock and are subject to the specified exercise price, expiration date, and four-year monthly vesting schedule under the equity plan.

Is Paul A. Wagner’s Form 4 transaction in FBRX shares a market buy or sell?

The transaction is not a market buy or sell. It is a grant of stock options as compensation, categorized as an acquisition under code A. No open-market purchase or sale of Forte Biosciences Common Stock is reported in this Form 4 filing.